Pharmaceutical Technology

JUNE 2, 2023

In a bit to challenge the market dominance of AbbVie’s Humira (adalimumab), the online pharmacy Cost Plus Drugs, owned by billionaire Mark Cuban has announced a plan to market Coherus Biosciences’ biosimilar Yusimry (adalimumab-aqvh), Cost Plus Drugs will be offering Yusimry at $569 per unit, excluding shipping and dispensing charges.

Biosimilars 52

Biosimilars Online Pharmacies Drug Pricing Communication 52

Drug Channels

OCTOBER 5, 2021

I am pleased to announce our new 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. analyzes how marketplace dynamics of provider-administered biosimilars affect wholesalers’ gross margins. Section 4.4. Section 7.4.4. Section 6.1.5. WHAT’S GOING ON.

Biosimilars 75

Biosimilars Pharmaceutical Manufacturing Hospitals Documentation 75

Drug Channels

MARCH 14, 2023

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Analyzes Impact of Inflation Reduction Act on U.S. Read on for some additional details.

Drug Pricing 98

Drug Pricing Biosimilars 98

Drug Channels

OCTOBER 11, 2022

I am pleased to announce our new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: U.S.

Biosimilars 74

Biosimilars Hospitals Pharmaceutical Manufacturing Documentation 74

Drug Channels

NOVEMBER 9, 2022

After the event, every registrant will receive a link to download the complete slide deck and have an opportunity to watch a replay of the live event. Fein will give participants an opportunity to unmute themselves and ask live questions. The webinar will last 90 minutes to accommodate audience questions. d/b/a Drug Channels Institute.

Specialty Pharmacies 98

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 98

Drug Channels

FEBRUARY 21, 2023

Those who preorder will receive a download link before March 14. CLICK HERE to download a free pre-publication overview (including key industry trends, the Table of Contents, and a List of Exhibits). Download a free report overview for more details on the new sections and content.

Specialty Pharmacies 97

Specialty Pharmacies Drug Pricing Biosimilars 97

pharmaphorum

AUGUST 11, 2022

Rebecca speaks about generics and biosimilars: what they are, why they’re important for medication access and healthcare cost sustainability, and what Sandoz has learned about succeeding in the off-patent world. She also touches on the patient stories behind the headlines and the effect of COVID-19 on the generics market.

Biosimilars 52

Biosimilars 52

pharmaphorum

FEBRUARY 12, 2021

Francis was previously CEO of Sandoz, Novartis’ generics and biosimilars division, where he led the development of biosimilars and also sat on the Swiss pharma company’s executive committee. He also outlines the challenges facing the gene therapy market and his immediate plans for Purespring.

Biosimilars 52

Biosimilars 52

Drug Channels

NOVEMBER 8, 2021

LANDSCAPE ADDRESS: Analyze Market Dynamics and Trends Impacting the Channel in an Ever-Changing Environment POLICY ADDRESS: Break Down Evolving Regulatory Reform Driving Innovation and Access Predict Novel Reimbursement Mechanisms and First Pharmacy Benefits for Biosimilars Download your copy of the agenda today and join Informa Connect in December!

Specialty Pharmacies 75

Specialty Pharmacies Biosimilars 75

Pharmaceutical Technology

DECEMBER 9, 2022

Instead, the focus remains on its domestic industry, particularly around biosimilars, while reducing reliance on imports and branded pharmaceuticals. To find out more about the key pharma markets in Latin America, download the specially commissioned whitepaper below. Please check your email to download the Whitepaper.

Drug Pricing 98

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 98

Drug Channels

OCTOBER 23, 2023

Exclusive Offer–Download the agenda and register today –Be sure to use your exclusive promo code 23DC10 to save 10% off * of your registration. Exclusive Offer–Download the agenda and register today –Be sure to use your exclusive promo code 23DC10 to save 10% off * of your registration. Why should you attend this pivotal event?

Biosimilars 75

Biosimilars 75

Drug Channels

SEPTEMBER 17, 2024

Those who preorder will receive a download link before October 8. We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2024-25 edition at special discounted prices. This means that you can be among the first to access our new report.

Biosimilars 52

Biosimilars 52

Drug Channels

SEPTEMBER 12, 2023

Those who preorder will receive a download link before October 10. CLICK HERE to download a free pre-publication overview (including key industry trends, the Table of Contents, and a List of Exhibits) You can pay online with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal.

Biosimilars 40

Biosimilars 40

Big Molecule Watch

AUGUST 25, 2023

With the IRA, Congress changed the pricing model for certain “high-priced” Medicare-covered drugs without generic or biosimilar competition. Drugs are considered to be “qualifying single-source drugs” if they have been without generic or biosimilar competition for a certain number of years.

Drug Pricing 40

Drug Pricing Biosimilars Insurance Coverage and Processing Labelling 40

Pharmaceutical Technology

JANUARY 16, 2023

However, low-cost generic and biosimilar manufacturers are likely to be particularly exposed to these economic pressures. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies. Please check your email to download the Report. By GlobalData. United Kingdom. United States.

Drug Pricing 64

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 64

pharmaphorum

OCTOBER 7, 2020

Pepa has 15 years of combined experience in Regulatory Affairs (CMC) and multiple aspects of drug development and research and has participated in the approval of 15 original and biosimilar biologic license applications, focusing on microbiology product quality and sterility assurance aspects.

Biosimilars 52

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Pharmaceutical Technology

JANUARY 16, 2023

However, low-cost generic and biosimilar manufacturers are likely to be particularly exposed to these economic pressures. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies. Please check your email to download the Report. By GlobalData. United Kingdom. United States.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

HealthPartners

JULY 21, 2021

We monitor the drug pipeline to predict and plan for new and lower-cost drug options like generics and biosimilars. Biosimilars are often good alternatives to expensive, bio-engineered “biologic” drugs because they are structurally “highly similar” and have no meaningful clinical differences. Alternative biosimilars.

Biosimilars 52

Biosimilars Specialty Pharmacies Mail-Order Pharmacies Health Insurance Companies 52

FDA Law Blog: Biosimilars

MARCH 7, 2023

It must first be downloaded, revised, and uploaded back to the system. Many teams use cloud-based file sharing systems to work collaboratively on files. Unfortunately, we have found that the eSTAR template PDF file does not work on these platforms.

Documentation 59

Documentation Communication 59

FDA Law Blog: Biosimilars

SEPTEMBER 23, 2024

The Paragraph IV Certifications List began as a web-based list on FDA’s website, and eventually transformed into a PDF downloadable list. FDA responded to the Citizen Petitions on February 27, 2004, and issued a Press Release on March 2, 2004 (yeah, we saved that as well) concerning the PIV List.

Dosage 59

Dosage Drug Pricing 59

Putting Patients First Blog

JANUARY 27, 2025

Formulary Inclusion and Placement of Generics and Biosimilars The NHC supports CMS proposals to improve formulary practices by prioritizing access to generics, biosimilars, and other cost-effective medications in the Medicare Part D program.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

Quality Matters

JUNE 17, 2024

Biologics and biosimilars – the basics Biologic medicines – “biologics” for short. And what about “biosimilars” ? Read on to learn some of the basics about biologics, biosimilars and why patients taking them can be confident in their quality. What are biosimilars? You’ve probably seen commercials for some of them on TV.

Biosimilars 52

Biosimilars Dosage Immunity Immunization 52

Pharmaceutical Technology

OCTOBER 28, 2022

Practising QbD in biosimilar product development. One area in which QbD should be practised is that of biosimilars, also known as follow-on biologics or subsequent entry biologics. Biosimilars are biologic medical products that almost exactly replicate products already being manufactured by other companies.

Biosimilars 52

Biosimilars Vaccines Drug Development Documentation 52

Drug Channels

FEBRUARY 22, 2022

Those who preorder will receive a download link before March 15. CLICK HERE to download a free pre-publication overview. We also present a more unified outlook for specialty drugs, including specialty generics and biosimilars. Download a free report overview for more details.

Specialty Pharmacies 96

Specialty Pharmacies Drug Pricing Biosimilars Vaccines 96

Drug Channels

OCTOBER 10, 2023

I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: U.S.

Specialty Pharmacies 40

Specialty Pharmacies Biosimilars Pharmaceutical Manufacturing Documentation 40

Pharmaceutical Technology

APRIL 12, 2023

For example, in 2021 the Medicines and Healthcare products Regulatory Agency (MHRA) published its first comprehensive guideline on biosimilars , which provided clear recommendations onthe requirements for animal and clinical efficacy studies. Download the full report to understand what to expect and how to align your strategies for success.

Vaccines 98

Vaccines Biosimilars Communication Pharmaceutical Companies 98

Pharmaceutical Technology

DECEMBER 22, 2022

You will also soon be able to download our full Awards & Rankings Report which includes all of this year’s rankings, as well as the awards winners, shortlists and company profiles. Business Expansion. It was also announced that the organisation would enter into collaboration with the Juvenile Diabetes Research Foundation (JDRF).

Diabetes 52

Diabetes Biosimilars Pharmaceutical Companies Pharmaceutical Companies 52

Quality Matters

APRIL 20, 2023

USP’s latest such tool – the Nitrosamines Analytical Hub housed within USP’s Nitrosamines Exchange online community for sharing knowledge and solutions – is a public, web-based repository of downloadable analytical procedures to test for nitrosamine impurities in pharmaceuticals.

Biosimilars 52

Biosimilars Labelling Vaccines Generic Medicine 52

RX Note

FEBRUARY 23, 2023

. - Drug registration number Medicines (Advertisement & Sale) Act 1956 and Regulations - To learn prohibitions of medicine advertisement and Medicine Advertisement Board Registration of Pharmacists Act 1951 and Regulations - Pharmacy Board Malaysia and legislation aspects of provisional, full and temporary registration Code of Ethics for Pharmacists (..)

HIV Treatment and Prevention Agents 58

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 58